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Objective: This retrospective single-center study analyzed long-term results after LifePath (Edwards Lifesciences LLC,
Irvine, Calif) endoprosthesis implantation for abdominal aortic aneurysm (AAA), primarily focusing on the wire form
fracture issue and consecutive endoleak rate.
Methods: Between 1999 and 2004, all consecutive patients with LifePath AAA devices in our institution were included in
the retrospective analysis. All patients had computed tomography angiography (CTA) imaging preoperatively and image
postprocessing. The follow-up using CTA imaging specifically addressed material fatigue (wire form fractures) resulting
in migrations and type I endoleaks.
Results: During the 6-year study period, which included the 1-year withdrawal and redesign of the device, 51 patients
were treated with LifePath AAA endografts. The 30-day mortality was 0%. The perioperative 30-day morbidity was 9.8%.
One patient required a primary conversion due to misdeployment of the iliac limbs within the graft main body. The
primary endoleak rate was 20.56% (type I, 2%; type II, 19.6%). During the mean follow-up of 40.7 months, 12 patients
died, six were lost to follow-up, and 32 underwent subsequent CTA imaging. Eight patients (25%) demonstrated a
proximal type I endoleak, seven (22%) had a type II endoleak, and three had a type III endoleak (9%). In nine patients
(28.1%), wire form fractures could be detected at image postprocessing. Four patients required a secondary conversion
due to endoleak and aneurysm growth (2 type I endoleaks and 2 type III endoleaks).
Conclusion:Wire form fracture is the major structural problem in the LifePath balloon-expandable endograft device, resulting
in a significant endoleak rate. We must caution those patients with a LifePath device in-situ that careful follow-up must be
performed due to material fatigue and they should consider secondary conversion. (J Vasc Surg 2009;50:479-85.)The era of endovascular aortic repair (EVAR) of infra-
renal abdominal aortic aneurysms (AAA) initially started
with the use of balloon-expandable anchoring Palmaz
stents (Cordis, Miami Lakes, Fla) in homemade devices.1
EVAR using commercially manufactured endografts with
self-expanding stent components has been evaluated dur-
ing the last decade as a viable treatment option for infrare-
nal AAA repair.2 The long-term effectiveness of the proce-
dure depends on a fluid-tight seal between the device and
the aortic wall, in the landing zones, and especially at the
level of the proximal aortic neck.3
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doi:10.1016/j.jvs.2009.04.026Generally there are two different concepts for EVAR in
AAA:
1. Self-expanding stent graft (SES) systems with a nitinol
endoskeleton or exoskeleton that springs open after
blood contact and within body temperature, and
2. Balloon-expandable stent graft (BES) systems that use a
large noncompliant percutaneous transluminal angioplasty
(PTA) balloon to deploy the device in the target vessel.
When it was introduced, the LifePath AAA Endopros-
thesis was the only commercially designed and developed
BES. It was distributed from 1997 to 2004 (Edwards
Lifesciences LLC, Irvine, Calif), but was withdrawn from
the market due to wire form fractures in 2000 and re-
launched in 2001 with modified wire forms.
Theoretically, one of the main advantages of a BES
system is the high precision and accuracy during proximal
and distal deployment due to slow, controlled device open-
ing and the possibility of repositioning. As a result of the
exact graft positioning, the rates of additional cuff place-
ment for treating proximal endoleaks are low (3.9%).4,5
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iliac limbs of BES dealing with calcified iliacs as deployed in
the kissing-balloon technique might be responsible for a near
complete absence of iliac limb occlusions that are observed
with SES.3,4 Complex infrarenal morphologies with angu-
lated necks can also be treated with BES that straighten the
angulation to protect against proximal endoleaks.4-7
Two generations of LifePath endografts have been
launched. After wire form fractures were observed at the
level of the three top wires of the main body of generation
I stents (1997 to June 2000; 42 months), the generation II
device, with modified and strengthened wire forms was
relaunched in September 2001 to June 2004 (34 months).
Short-term and midterm results for the LifePath system
were published in a multicenter pivotal trial in 2004 by Car-
penter et al.4 As a centerwith expertise inBES,withmore than
50 implantations, we started this retrospective clinical study to
obtain long-term results for theLifePath system,with a special
focus on the development of secondary type I endoleaks and
the occurrence of wire form fractures in the device.
METHODS
Patient characteristics. During the 62 months be-
tweenMarch 1999 andMay 2004, 182 patients underwent
elective EVAR for AAA in our department using different
endograft devices. Among those, 51 patients (28%) were
treated with a LifePath AAA bifurcation device. Of the 51
LifePath devices implanted, 20 (39.2%) were from genera-
tion I and 31 (60.8%) were from generation II. All patients
with LifePath devices were primary enrolled for a clinical
trial. The trial-specific monitoring stopped after the LifePath
was withdrawn from the market in 2004. Afterwards, an-
nual clinical investigation and imaging according to our
institute-specific follow-up policy was performed.
One woman and 50 men were treated during the
observation period. The mean age of the patients was 69.1
years (range 58-84 years), and themean diameter of treated
aneurysms was 5.3 cm (range, 4.0-6.5 cm). One patient
had a symptomatic aneurysmwith a 4.0-cm diameter. All of
the analyzed demographic data are listed in Table I.
EVARwas done under general anesthesia in 49 patients
(96.1%), and local anesthesia was used with two (3.9%).
Patients that fulfilled clinical indication for aortic repair and
morphological feasibility criteria for endovascular treat-
ment (Heidelberg AAA Classification)8 were included in
the retrospective study.
Patient selection. The inclusion criteria for EVARwere
as follows: aneurysm diameter 50 mm, symptomatic or
saccular aneurysm, aneurysm growing 5 mm/y, age 85
years, patient availability for future follow-up investigations,
proximal neck diameter 28 mm, aortic neck length 15
mm, aortic neck angulation 60°, suitable iliac attachment
zone, and suitable femoral access side8 mm. If the femoral
access site was8 mm, an iliac conduit was performed.
The investigation excluded patients with rupture, para-
anastomotic AAAs, or bilateral hypogastric AAAs.
Device selection. The anatomic suitability for EVAR
was determined by computed tomographic angiography(CTA). Routine preoperative catheter angiography was not
performed. Preoperative measurements of the aneurysm
neck diameter were used for sizing the stent graft main
body. Minimal oversizing of 5% to 8% was used. The
implanting surgeon selected the graft, and graft length was
chosen to avoid covering one hypogastric artery.
Deployment procedure. All procedures were per-
formed in the operating room using a portable C-arm fluoro-
scopic devicewith digital imaging and road-mapping capacity.
The device was inserted through a femoral cutdown or when
necessary (femoral artery 0.8 mm) through retroperitoneal
access with an iliac Dacron conduit.
Completion angiography at the end of the proce-
dures confirmed successful deployment as well as ade-
quate fixation and position of the endograft. If a type I
endoleak was detected intraoperatively, further treat-
ment (proximal cuff, iliac extensions) was performed
during that operation. Type II endoleaks were primarily
accepted without further treatment. Primary conversion
to an open operation was indicated if safe placement of
the endovascular device was difficult or impossible as a
result of an anatomic peculiarity.
Image analysis. All patients underwent contrast-
enhanced CTA before the intervention and postoperatively
during the same hospital stay. Endoleaks were defined
using the definition published by White et al.9
The integrity of the wire form of the stent graft was
analyzed using conventional radiographs and also by
3-dimensional volume rendering CTA (3D-CTA).
Follow-up. Patients underwent clinical examination,
plain radiographs, and routine CTA checks before hospital
discharge, after 6 months, and annually thereafter. Consec-
utive CT scans and radiographs were analyzed, and postop-
erative imaging and final imaging were compared.
Statistical analysis. Fisher exact two-tailed test (f test)
and the log-rank (Mantel-Cox) were used to compare both
generations of LifePath prosthesis using MedCalc (MedCalc
Table I. Demographics and comorbidities
Variable No (%) Mean (range)
Total patients 51
Age, y 69.1 (58-84)
Sex
Female 1 (1.96)
Male 50 (98.14)
Aneurysm size, cm 5.3 (4.0-6.5)
Symptomatic aneurysm 1 (1.96)
Hypertension 45 (88.24)
Coronary heart disease 29 (56.87)
Pre-op renal insufficiency 8 (15.68)
COPD 13 (25.5)
Smoking 21 (41.18)
ASA I-II 17 (33.33)
ASA III-IV 34 (66.67)
ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease.Software, Mariakerke, Belgium).
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Technically successful implantations were possible in
98% of the patients. One patient (1.96%) needed primary
conversion caused by endograft limb misplacement, and
another patient underwent an intraoperative corrective
procedure (proximal cuff) for proximal sealing due to en-
doleak type I. The mean operation time was 135.2 minutes
(range, 83-310 minutes).
Early outcome. No patients died during the 30-day
observation period. One patient (1.96%) died during a
hospital stay 68 days after the implantation procedure due
to multiorgan failure after ischemic colon perforation.
The overall in-hospital morbidity including cardiac,
pulmonary, renal, and neurologic events was at 9.8% (5
patients).
One patient underwent repeat intervention with im-
plantation of a crossover bypass after iliac dissection. The
patient with primary conversion showed severe complica-
tions with colon ischemia and additional peripheral embo-
lization and required a colectomy and iliac bypasses.
Short-term imaging data. Before discharge, 92.2% of
the patients underwent postoperative CTA. Primary en-
doleaks could be detected in 21.56%, consisting of one type
I (1.96%) and 10 type II (19.6%) endoleaks. The patient
with the proximal type I endoleak had a malignancy and
refused a corrective procedure. The patient died 1 year after
EVAR of causes not related to the procedure itself. Nine
type II endoleaks were caused by lumbar arteries (17.65%)
and one by an inferior mesenteric artery (1.96%). All were
treated conservatively (Table II).
Late outcome. During the mean follow-up of 40.7
months, 12 of the 51 patients (23.5%) died. Their mean
survival after endograft implantation was 22.8 months
(range, 4-49.9 months). Six patients (11.8%) could not be
located at the time of follow up. There was no difference in
survival for the generation I and generation II patients
Table II. In-hospital outcome
Outcome No (%) or mean (range)
Patients, total 51
Mortality
30-day 0 (0)
In-hospital 1 (1.96)
Primary conversion 1 (1.96)
Primary endoleaks 11 (20.52)
Type I 1 (1.96)
Type II 10 (19.6)
Operation time, min 135.2 (83-310)
General anesthesia, 49 (96.1)
Intra-op endovasc correction 1 (1.96)
Myocardial infarction 3 (5.88)
Renal complication 2 (3.92)
Pulmonary complication 0 (0)
Length of stay, d
Hospital 10.68 (5-68)
Intensive care unit 2.22 (1-50)(log-rank P  .89; Fisher exact test P  .74; Fig 1).Four patients required reoperation during the follow-up
period. One patient received thoracic endograft for a sec-
ondary thoracic aneurysm. One patient underwent femoral
thromboendarterectomy for peripheral artery disease. In-
tervention was required for a chronic lymphatic fistula at
the groin access site in one patient, and another patient
required a toe amputation because of peripheral arterial
occlusive disease that developed after primary conversion.
Long-term imaging data. A mean of four (range,
2-9) imaging controls by CT scan were performed. The 11
patients (21.5%) without further imaging after the hospital
stay included one patient with primary conversion, one
patient who died during the hospital stay, one patient with
a type I endoleak who refused further treatment, and eight
patients who died early after intervention or were lost to
follow-up.
Endoleaks. Themean follow-up period of the patients
was 40.7 months. Eight (25%) secondary proximal type I
endoleaks (Table III) were observed, two of which were
treated with interventional embolization, and two patients
needed secondary conversion for treatment. Four patients
with late contrast enhancement during CT analysis as a sign
of proximal endoleak indicated relevant regression of the
aneurysm sac and continue to be checked frequently. These
patients were at high risk for a conversion operation or
refused further treatment.
Two of the seven type II endoleaks were new in origin
and required no further treatment. Compared with the 10
primary detected type II endoleaks, five occluded sponta-
neously without treatment.
Type III endoleaks developed in three patients (9.5%)
at the leg docking area. One patient underwent successful
endovascular repair, and the other two required a second-
ary conversion procedure during follow-up. A Kaplan-
Meier analysis for freedom from endoleaks is provided in
Fig 2. There was no significant difference between the
occurrence in the two generations of stents for type I, II,
and III endoleak.
A total of four (12.5%) secondary conversion proce-
dures were necessary: two patients for type I and two
patients for type III endoleaks (Table III).
Wire form fractures. We found nine patients (28.1%)
with fractures in the wire form of the LifePath device. All
were localized at the top of the main body, which is a
well-known weakness of the device (Figs 3 and 4). Three of
these nine patients with wire form fractures presented type
I endoleaks. There was no difference in the occurrence of
wire form fractures between the generation I and II devices
(Fisher exact test, P  .99).
AAA sac regression. Sac regression during follow-up
was documented in 27 of 37 patients (73%) with a follow-up
imaging of more than 12 months. Seven patients (18.9%)
demonstrated sac enlargement, including four patients pre-
senting with type I endoleak and three with type II en-
doleak. Statistical analysis showed no significant difference
in sac regression rate between the two LifePath generations
(Fisher exact test, P  .31).
II, t
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The study analyzed the long-term performance of Ed-
wards LifePath AAA Endograft System. Compared with
the encouraging midterm results, our long-term data for
the LifePath system are poor, with a significant secondary
type I endoleak rate of 25%, a type III endoleak rate of
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I, the standard error never exceeded 10%; for generation
Table III. Follow-up outcome
Variable
No. (%), or mean (range)
N  51
Length of follow-up, mon 40.7 (1-91)
Follow-up mortality 12 (23.5)
Lost- to –follow-up 6 (11.8)
N  32
Secondary endoleaks 13 (40.6)
Type I 8
Type II 2
Type III 3
Secondary conversion 4 (12.5)
Type I 2
Type III 2
Secondary correction 5 (15.6)
Endovascular
Type I 2
Type II 2
Type III 1
Open 3 (9.4)9.5%, and a secondary conversion rate of 12.5%.Long-term durability of EVAR is known to be highly
dependent on the integrity of proximal fixation.8 Cur-
rently, most AAA endograft systems are based on SES
systems, and it is generally accepted that they be oversized
by 10% to 20%. The oversizing is needed to produce
enough radial force to prevent proximal endoleak.6 As a
result of oversizing, recent reports documented relevant
neck dilatation rates of 28% and migration of the devices in
25% of cases for SES.10 Alternative implantation devices
using a BES presented several advantages, such as exact
deployment and good results in early-term and long-term
follow-up.4,6,7,10,11 Malas et al6 presented data from the
Montefiore Endografting System (MEGS), with an en-
couraging absence of neck dilatation and graft migration in
their series. The MEGS System is Palmaz stent-based de-
vice with a polytetrafluoroethylene graft sutured to a me-
tallic skeleton. It presents the only balloon-expandable
alternative to the LifePath device. TheMEGS system uses a
different implantation principle (aortouniiliac with cross-
over bypass), and the construction provides the possibility
of suprarenal stent graft fixation.6,7,12,13
Taken together, BES-based prevention of proximal
radial aortic neck stress occurs with minimal oversizing of
only 5% to 10%.11 In this regard, a low rate of migration
and endoleak occurrence after LifePath implantation was
documented.4,5,10 The series by Dalainas et al10 reported a
rate of aortic neck dilatation and migration for the LifePath
device of only 7%. Remarkably, in two of these three
patients, they also recognized type I endoleak development
60 80 100
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1
2
and generation II (red) LifePath devices. For generation
he standard error exceeded 10% after 24 months.val
onths)
lue)during follow-up.10
endo
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 3 Ockert et al 483Harris et al14 also showed an absence of migration for
the Lifepath system in their analysis based on the European
Collaborators on Stent-Graft Techniques for Aortic Aneu-
rysm Repair (EUROSTAR) registry. In our series, the rate
of primary endoleaks was remarkably high (20%), but
mainly consisted of type II endoleaks. However, in contrast
to the published data for midterm follow-up,4 we found a
high rate of secondary endoleaks. Our oversizing rate was
moderate at 5% to 8% and comparable with other au-
thors3,5,8,10 and should not be the reason for the elevated
complication rate. Nevertheless, eight patients (25%) from
our series presented with proximal type I endoleaks, and
four required treatment. It is notable that our institution-
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Fig 2. Kaplan-Meier analysis for freedom of
Fig 3. Top-wire form fractures (arrows).specific secondary type I endoleak rate for SES is 2% to 3%.During long-term follow up, we saw three patients with
late type III endoleaks, and they all required secondary
intervention for treatment. One patient underwent an in-
terventional correction procedure (endovascular limb im-
plantation), and the other two required secondary conver-
sion.
Wire form fractures are a well-known problem with the
LifePath device.4,5 Although most fractures were without
clinical consequence, migration or endoleaks were associ-
ated with these fractures in several cases. As result of early
observations, the manufacturer strengthened the wire
forms to reduce this complication.
Our series documented a high incidence of wire form
fractures during long-term follow-up. Wire fractures were
detected in both generations of the system without group-
specific differences. Mostly the fractures were located at the
three top wire forms, as previously reported. Association of
type I endoleak and wire form fractures occurred in three
patients.
Sac regression is an indicator for determining successful
exclusion of the aneurysm from the blood flow. For the
LifePath prosthesis, sac regression is reported to be higher
than for all other devices, including self-expandable stents
(84% volume reduction in 1 year).4,5
In our series, nearly 75% of the patients showed a
reduction in sac diameter, indicating successful aneurysm
exclusion. Unfortunately, the CTA control showed seven
patients had an enlargement of the sac. The enlargement
was caused by secondary proximal type I endoleaks in four
patients, and three patients showed type II endoleaks.
Some substantial limitations in our work need to be
discussed. Our data demonstrates that only two-thirds of
the patients regularly received a CTA check-up for detec-
oleak
60 80 100
months)
8 7 1
leak. The standard error never exceeded 10%.End
Time (tion of endovascular complications. All other patients ex-
view
JOURNAL OF VASCULAR SURGERY
September 2009484 Ockert et alceeded intervals for CTA follow-up, so some patients with
EVAR-associated complications may have been missed. Of
the 18 patients (35.3%) who died or could not be located at
the time of follow-up, no information was available in
two-thirds about whether the death was aneurysm related.
CONCLUSIONS
In contrast to early reports on short-term and midterm
results of the LifePath endoprosthesis, the long-term results in
this series are poor. Clinical advanced outcome of the prosthe-
sis on a wire form-based balloon-expandable system was not
reproducible at long-term follow-up.TheLifePathAAAGraft
System was taken from the market in 2004 due to business
decisions from Edwards. Our results underline that major
construction problems are associatedwith both generations of
the graft. Material fatigue (wire form fractures) of the Elgiloy
stents (ElgiloyLimitedPartnership, Elgin, III) provoked stent
migration and an unacceptable rate of late type I endoleaks.
Patients who underwent Lifepath endovascular aortic repair
need regular and lifelong follow-up to prevent postprocedural
complications.
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